Results 61 to 70 of about 29,567 (180)
Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.ITGA5/integrin α5β1 promotes PDAC progression by integrating fibronectin‐dependent adhesion, hypoxia‐associated ECM remodelling, pancreatic stellate cell/cancer‐associated fibroblast activation, desmoplasia and tumour‒stroma crosstalk. These processes contribute to impaired drug delivery and therapeutic resistance.
Chenzhe Ma, Yingying Wang, Yumin Li
wiley +1 more source
Frontiers in Oncology, 2020 BackgroundRecently, various blood cell lineages expressing the BCR-ABL fusion gene in Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) have been reported. However, the biological and clinical significance of these BCR-ABL lineages
Satoshi Nishiwaki +14 more
doaj +1 more source
International Journal of Cancer, Volume 159, Issue 3, Page 797-808, 1 August 2026.A key component of the collagen internalization and lysosomal degradation cellular machinery, uPARAP may contribute to cancer progression. Here, the authors explored the expression of uPARAP in gastrointestinal stromal tumors using well‐annotated clinical patient samples and specimens from cell line‐ and patient‐derived xenografts.
Chao‐Chi Wang +10 more
wiley +1 more source
DETECTION OF BCR-ABL PROTEIN IN CHRONIC MYELOID LEUKEMIA PATIENTS USING IMMUNOCYTOCHEMISTRY
The Iraqi Journal of Medical Sciences, 2016 Background: Chronic Myeloid leukemia (CML) is a myeloproliferetive disorder associated with chromosomal abnormality, Philadelphia chromosome (Ph), in more than 95% of CML patients. The resulting BCR-ABL fused gene is markers for this type of leukemia. In
Maysaa Abdul Razaq Dhahi +2 more
doaj +6 more sources
eJHaem, Volume 7, Issue 4, August 2026.ABSTRACT Introduction In‐frame Exon 4 deletion (p.L184_K274del) is a rare ABL1 splicing variant in chronic myeloid leukemia (CML), the clinical significance of which remains unclear. Methods We retrospectively analyzed seven chronic‐phase CML patients with this variant, identified by Sanger sequencing during routine monitoring of atypically slow ...
Yuto Kaneda +10 more
wiley +1 more source
Protein Science, Volume 35, Issue 8, August 2026.Abstract The Protein Data Bank (PDB), established in 1971, is the primary global, open‐access archive for experimentally determined 3D macromolecular structures (proteins, RNA, DNA). The research‐focused RCSB.org web‐portal provides access to these data alongside more than one million machine‐learning‐predicted structure models, greatly expanding the ...
Yana Rose +8 more
wiley +1 more source
Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins.
The Journal of biological chemistry, 1998 A 62-kDa Ras GTPase-activating protein (RasGAP)-associated protein is tyrosine-phosphorylated under a variety of circumstances including growth factor stimulation and in cells transformed by activated tyrosine kinases. A cDNA for p62(dok), reported to be the RasGAP-associated 62-kDa protein, was recently cloned from Abl-transformed cells. In this study,
A, Bhat +4 more
openaire +2 more sources
Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.ABSTRACT Interindividual variability (IIV) in drug response complicates both fixed‐dose design and individualized therapy. Understanding how pharmacokinetic (PK) and pharmacodynamic (PD) processes jointly shape this variability is essential, particularly in combination therapy, where multiple interacting pathways influence outcomes. This study employed
Kuteesa R. Bisaso +3 more
wiley +1 more source
Quantitative Assessment of the BCR-ABL Transcript Using the Cepheid Xpert BCR-ABL Monitor Assay
Archives of Pathology & Laboratory Medicine, 2007 Abstract Context. —Chronic myelogenous leukemia (CML) and the assessment of the BCR-ABL transcript has become a new paradigm. Novel tyrosine kinase inhibitors as mainstream therapeutic options for the CML patient warrant routine quantification of the
Scott D, Dufresne +3 more
openaire +2 more sources
Chronotherapy in Hematological Malignancies: Evaluating the Rationale and Evidence
Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.ABSTRACT Hematological malignancies remain one of the leading causes of morbidity and mortality despite advances in targeted therapies, immunotherapy, and stem cell transplantation. Emerging evidence indicates that treatment efficacy and toxicity depend not only on the choice of therapy but also on its timing relative to the patient's internal ...
Andrej Belančić +7 more
wiley +1 more source